Investigation on the prevalence of polycystic ovary syndrome (PCOS) in college female students and explore the efficacy of muscle enhancement intervention in lean PCOS patients on changing of plasma androgen, gut microbiota and plasma metabolome after treatment

Efficacy of muscle enhancement intervention in lean PCOS patients on changing of plasma androgen, gut microbiota and plasma metabolome after treatment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065463

Enrollment

Unknown

Registered

2022-11-04

Start date

2022-11-14

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome (PCOS)

Interventions

PCOS group:Impedance training was combined with whey protein powder orally for muscle augmentation

Lean healthy volunteers:Impedance training was combined with whey protein powder orally for muscle augmentation

Eligibility

Sex/Gender

Female

Age

18 Years to 24 Years

Inclusion criteria

Inclusion criteria: PCOS patients: 1. PCOS diagnostic criteria: according to the Rotterdam criteria, meet: menstrual thinning or anovulation; Clinical manifestations or biochemical evidence of hyperandrogenemia; Ovarian ultrasound showed that the number of vesicles with a diameter of 2-9 mm on each side was greater than or equal to 12, which met the criteria of more than 2, and excluded congenital adrenal hyperplasia (CAH), Cushing syndrome, hyperprolactinemia and thyroid dysfunction; 2. Aged 18-24 years; 3. BMI < 22 kg/m^2; 4. No PCOS related treatment (including Diane-35, metformin, etc.) in the past 3 months; Lean volunteers: 1. Healthy female; 2. Aged 18-24 years; 3. BMI < 22 kg/m^2.

Exclusion criteria

Exclusion criteria: PCOS patients and healthy volunteers used the same exclusion criteria: 1. Patients with chronic diseases such as diabetes, hypertension and connective tissue disease need long-term medication; 2. Patients with endocrine diseases such as thyroid, adrenal and gonadal diseases who need long-term medication; 3. Patients with intestinal diseases such as inflammatory bowel disease, or receiving intestinal surgery; 4. Severe liver, kidney and heart dysfunction; 5. Patients used antibiotics and probiotics in recent 3 months.

Design outcomes

Primary

Measure	Time frame
Human components analysis;Plasma androgen measurement;Gut microbiota;Plasma metabolome (untargeted);	—

Secondary

Measure	Time frame
Measurement of FKBP5 DNA methylation;	—

Countries

China

Contacts

Public ContactGuoshu Yin

The First Affiliated Hospital of Shantou University Medical College

yinguoshu@126.com+86 13417029106

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026